422 related articles for article (PubMed ID: 21216488)
21. Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer.
Gori B; Ricciardi S; del Signore E; Fulvi A; de Marinis F
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S55-60. PubMed ID: 22443258
[TBL] [Abstract][Full Text] [Related]
22. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
Morita S; Okamoto I; Kobayashi K; Yamazaki K; Asahina H; Inoue A; Hagiwara K; Sunaga N; Yanagitani N; Hida T; Yoshida K; Hirashima T; Yasumoto K; Sugio K; Mitsudomi T; Fukuoka M; Nukiwa T
Clin Cancer Res; 2009 Jul; 15(13):4493-8. PubMed ID: 19531624
[TBL] [Abstract][Full Text] [Related]
23. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
Kondo M; Yokoyama T; Fukui T; Yoshioka H; Yokoi K; Nagasaka T; Imaizumi K; Kume H; Hasegawa Y; Shimokata K; Sekido Y
Lung Cancer; 2005 Dec; 50(3):385-91. PubMed ID: 16140420
[TBL] [Abstract][Full Text] [Related]
24. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
[TBL] [Abstract][Full Text] [Related]
25. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.
Wu YL; Fukuoka M; Mok TS; Saijo N; Thongprasert S; Yang JC; Chu DT; Yang JJ; Rukazenkov Y
Lung Cancer; 2013 Aug; 81(2):280-7. PubMed ID: 23540718
[TBL] [Abstract][Full Text] [Related]
26. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials.
Petrelli F; Borgonovo K; Cabiddu M; Barni S
Clin Lung Cancer; 2012 Mar; 13(2):107-14. PubMed ID: 22056888
[TBL] [Abstract][Full Text] [Related]
28. Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
Dongiovanni D; Daniele L; Barone C; Dongiovanni V; Fissore C; Sapino A; Macrì L; Bussolati G; Buffoni L; Gaspari F; Grillo R; Birocco N; Addeo A; Ciuffreda L; Schena M
Lung Cancer; 2008 Jul; 61(1):73-81. PubMed ID: 18243402
[TBL] [Abstract][Full Text] [Related]
29. Gefitinib for the treatment of non-small-cell lung cancer.
Campbell L; Blackhall F; Thatcher N
Expert Opin Pharmacother; 2010 Jun; 11(8):1343-57. PubMed ID: 20426712
[TBL] [Abstract][Full Text] [Related]
30. Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.
Gridelli C; Ardizzoni A; Douillard JY; Hanna N; Manegold C; Perrone F; Pirker R; Rosell R; Shepherd FA; De Petris L; Di Maio M; de Marinis F
Lung Cancer; 2010 Jun; 68(3):319-31. PubMed ID: 20036027
[TBL] [Abstract][Full Text] [Related]
31. First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer.
Lange T; Müller-Tidow C; Serve H; Hoffknecht P; Berdel WE; Thomas M
Oncol Rep; 2005 Dec; 14(6):1539-42. PubMed ID: 16273252
[TBL] [Abstract][Full Text] [Related]
32. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
Mitsudomi T; Kosaka T; Endoh H; Horio Y; Hida T; Mori S; Hatooka S; Shinoda M; Takahashi T; Yatabe Y
J Clin Oncol; 2005 Apr; 23(11):2513-20. PubMed ID: 15738541
[TBL] [Abstract][Full Text] [Related]
33. Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines.
de Marinis F; Rossi A; Di Maio M; Ricciardi S; Gridelli C;
Lung Cancer; 2011 Jul; 73(1):1-10. PubMed ID: 21440325
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer.
Lara-Guerra H; Waddell TK; Salvarrey MA; Joshua AM; Chung CT; Paul N; Boerner S; Sakurada A; Ludkovski O; Ma C; Squire J; Liu G; Shepherd FA; Tsao MS; Leighl NB
J Clin Oncol; 2009 Dec; 27(36):6229-36. PubMed ID: 19884551
[TBL] [Abstract][Full Text] [Related]
35. First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901.
Takahashi K; Saito H; Hasegawa Y; Ando M; Yamamoto M; Kojima E; Sugino Y; Kimura T; Nomura F; Ogasawara T; Shindoh J; Yoshida N; Suzuki R
Cancer Chemother Pharmacol; 2014 Oct; 74(4):721-7. PubMed ID: 25087097
[TBL] [Abstract][Full Text] [Related]
36. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.
Niho S; Kubota K; Goto K; Yoh K; Ohmatsu H; Kakinuma R; Saijo N; Nishiwaki Y
J Clin Oncol; 2006 Jan; 24(1):64-9. PubMed ID: 16382114
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of gefitinib during pregnancy: case report and literature review.
Gil S; Goetgheluck J; Paci A; Broutin S; Friard S; Couderc LJ; Ayoubi JM; Picone O; Tcherakian C
Lung Cancer; 2014 Sep; 85(3):481-4. PubMed ID: 24997732
[TBL] [Abstract][Full Text] [Related]
38. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
39. Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
Reck M; Gatzemeier U
Lung Cancer; 2005 Oct; 50(1):107-14. PubMed ID: 15985306
[TBL] [Abstract][Full Text] [Related]
40. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
Inoue A; Suzuki T; Fukuhara T; Maemondo M; Kimura Y; Morikawa N; Watanabe H; Saijo Y; Nukiwa T
J Clin Oncol; 2006 Jul; 24(21):3340-6. PubMed ID: 16785471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
